Sienna Biopharmaceuticals (NASDAQ:SNNA) had its target price reduced by BMO Capital Markets from $27.00 to $17.00 in a report published on Tuesday, The Fly reports. BMO Capital Markets currently has an outperform rating on the stock.
Separately, Cowen set a $45.00 price objective on Sienna Biopharmaceuticals and gave the stock a buy rating in a research report on Monday.
Shares of SNNA opened at $5.40 on Tuesday. The stock has a market capitalization of $122.61 million, a P/E ratio of -1.04 and a beta of 1.57. Sienna Biopharmaceuticals has a 1-year low of $5.06 and a 1-year high of $25.71. The company has a debt-to-equity ratio of 0.67, a quick ratio of 4.86 and a current ratio of 4.86.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Sienna Biopharmaceuticals by 11.2% during the 3rd quarter. Vanguard Group Inc. now owns 667,819 shares of the company’s stock worth $9,897,000 after acquiring an additional 67,240 shares during the period. Morgan Stanley boosted its position in Sienna Biopharmaceuticals by 39.1% during the 3rd quarter. Morgan Stanley now owns 544,429 shares of the company’s stock worth $8,068,000 after acquiring an additional 153,014 shares during the period. Jane Street Group LLC acquired a new stake in Sienna Biopharmaceuticals during the 3rd quarter worth about $182,000. Partner Fund Management L.P. boosted its position in Sienna Biopharmaceuticals by 1.6% during the 3rd quarter. Partner Fund Management L.P. now owns 1,576,311 shares of the company’s stock worth $23,361,000 after acquiring an additional 25,018 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in shares of Sienna Biopharmaceuticals during the 3rd quarter valued at about $200,000. Hedge funds and other institutional investors own 48.18% of the company’s stock.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Further Reading: Price to Earnings Ratio (PE), For Valuing Stocks
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.